26 May 2013
Keywords: abbott, says, atrasentan, trial, misses, endpoint, laboratories
Article | 17 February 2003
Abbott Laboratories has halted a Phase III trial of one its late-stagepipeline drugs, atrasentan for prostate cancer, after the study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 February 2003
24 May 2013
© 2013 thepharmaletter.com